Last reviewed · How we verify
RV299 (rv299)
At a glance
| Generic name | rv299 |
|---|---|
| Sponsor | Pfizer Inc. |
| Phase | Phase 1 |
Approved indications
Common side effects
- Headache
- Dizziness
- Malaise
- Upper respiratory tract infection
- Nausea
- Syncope
- Vessel puncture site bruise
- Chills
- Urinary tract infection
- Diarrhoea
- Mouth ulceration
- Blood potassium increased
Key clinical trials
- Safety, Pharmacokinetics,and Antiviral Activity of RV299 Against Respiratory Syncytical Virus (RSV) (PHASE1)
- Safety, Tolerability, Pharmacokinetics, and Food Effect Study of RV299 in Healthy Adults (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RV299 CI brief — competitive landscape report
- RV299 updates RSS · CI watch RSS
- Pfizer Inc. portfolio CI